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ABSTRACT
Cyclin D1 is an important molecular driver of human breast cancer but better
understanding of its oncogenic mechanisms is needed, especially to enhance efforts
in targeted therapeutics. Currently, pharmaceutical initiatives to inhibit cyclin D1
are focused on the catalytic component since the transforming capacity is thought
to reside in the cyclin D1/CDK activity. We initiated the following study to directly
test the oncogenic potential of catalytically inactive cyclin D1 in an in vivo mouse
model that is relevant to breast cancer. Herein, transduction of cyclin D1–/– mouse
embryonic fibroblasts (MEFs) with the kinase dead KE mutant of cyclin D1 led to
aneuploidy, abnormalities in mitotic spindle formation, autosome amplification,
and chromosomal instability (CIN) by gene expression profiling. Acute transgenic
expression of either cyclin D1WT or cyclin D1KE in the mammary gland was sufficient
to induce a high CIN score within 7 days. Sustained expression of cyclin D1KE induced
mammary adenocarcinoma with similar kinetics to that of the wild-type cyclin D1.
ChIP-Seq studies demonstrated recruitment of cyclin D1WT and cyclin D1KE to the
genes governing CIN. We conclude that the CDK-activating function of cyclin D1 is
not necessary to induce either chromosomal instability or mammary tumorigenesis.

mammary tumorigenesis in mice [3]. Cyclin D1 encodes
the regulatory subunit of the cyclin-dependent kinase
(CDK4/6) holoenzyme. Tumors overexpressing cyclin
D1 tend to display normal levels of proliferation and
expression of E2F target genes, which contrasts with tumors
overexpressing cyclin E or an activator for pRb [4, 5]. Breast
cancers overexpressing cyclin D1 that are wild type for
pRb have relatively normal proliferation rates, in contrast
to those caused by genetic inactivation of pRb, which show

INTRODUCTION
Activation of the cyclin D1 oncogene, often by
amplification or rearrangement, is a major driver of
multiple types of human tumors including breast and
squamous cell cancers, B-cell lymphoma, myeloma,
nd parathyroid adenoma [1, 2]. The cyclin D1 gene is
amplified or overexpressed in up to half of human breast
cancers and its mammary-targeted overexpression induces
www.impactjournals.com/oncotarget
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of cyclin D1WT in cyclin D1-deficient cells results in
CIN [22]. In order to test the kinase-independent function
of cyclin D1 in aneuploidy and tumorigenesis, we utilized
a cyclin D1 point mutant, cyclin D1 K112E (cyclin
D1KE), which contains a lysine to glutamine substitution
at amino acid position 112 (Supplementary Figure S1A).
The cyclin D1KE mutant was unable to bind CDKs in vitro
[27]. Cyclin D1KE immunoprecipitated CDK4 and CDK6,
and could efficiently bind p27Kip1, however in an in vitro
kinase assay the cyclin D1KE complex showed dramatically
reduced phosphorylation of pRb [28]. Cyclin D1KE in vivo
binds CDK4 and p27Kip1 however the phosphorylation of
pRb in vivo was reduced similar to levels seen in cyclin
D1–/– mice [29]. In MEFs cyclin D1KE failed to bind CDK4
or p27Kip1 [16]. Collectively these studies demonstrate
that the kinase function of cyclin D1KE is abrogated or
substantially blunted.
Prior to engaging in studies to question whether
the induction of aneuploidy by cyclin D1 is kinaseindependent we verified the relative abundance and
nuclear localization of cyclin D1KE. In cyclin D1–/– cells
rescued with either cyclin D1WT or cyclin D1KE, the
protein abundance was similar between the two cell
lines (Supplementary Figure S1B). In addition there
was no difference in the abundance within the nuclear
compartment (Supplementary Figures S1C and S1D). Next
we, determined the subcellular compartmentalization of
cyclin D1KE and cyclin D1WT. We compared 3T3 wild
type cells to 3T3 wild type cells transduced with MSCVCyclin D1KE and the localization of exogenous cyclin D1KE
and endogenous cyclin D1WT protein monitored during
aphidocoline block in G1 to release into S phase. Cyclin
D1KE, like endogenous cyclin D1WT, was exported from
the nucleus to the cytoplasm (Supplementary Figure S2).
Next, to determine whether the alterations in mitotic
abnormalities were induced by cyclin D1WT via its CDKactivating function, we performed immunofluorescence
followed by high resolution confocal imaging of cyclin
D1–/– 3T3 cells, rescued with either cyclin D1WT or cyclin
D1KE (Figure 1A). The number of cells with multi-polar
spindles was increased 28% in the cyclin D1–/–D1 Rescue cells
and 31% in the cyclin D1–/–KE Rescue cells compared to control
(p = 0.0051 and p = 0.0004 respectively) (Figures 1A
and 1B). The generation of multi-polar spindle cells
arising from abnormalities in centrosome number and
distribution were quantitatively assessed using α-tubulin
staining in conjunction with γ-tubulin. The cyclin D1-/-D1
Rescue
and the cyclin D1–/–KE Rescue increased the percentage of
prometaphase/metaphase cells with multiple centrosomes
by 20% (p = 0.0021) and 28% (p = 0.0007) respectively
compared to control cells (Figures 1A and 1C).
The alteration of spindle architecture associated with
metaphase plate disruption was measured by assessing
metaphase plate length and width (ChL, Chw) and spindle
length and width (SpL, SpW) (Figures 1D and 1E).
Consistent with the increase in spindle/centrosome
abnormalities, the ChW and SpL were significantly

significantly increased proliferation rates [4–6]. Furthermore,
the alternate splice form of cyclin D1, (cyclin D1b), has
potent transforming ability, which does not correlate with
the ability to phosphorylate the pRb protein [7, 8].
Much of the early work defined kinase-dependent
functions of cyclin D1 (reviewed in [9]). Cyclin D1/CDK4/6
phosphorylates the retinoblastoma protein (pRb) to advance
the G1S and phosphorylates NRF-1 to inhibit mitochondrial
biogenesis thereby coordinating nuclear and mitochondrial
functions [10–13]. Cyclin D1 regulates a pool of mammary
progenitor cells (parity-identified mammary cells: PI-MEC)
is kinase-dependent. The resistance of cyclin D1-/-/MMTVErbB2 mice to ErbB2 driven mammary tumors is thought to
be dependent on a complete absence of PI mammary cells
in cyclin D1-null mice [14]. Several other kinase-dependent
properties of cyclin D1 have been identified including the
induction of cellular migration, enhanced angiogenesis and
mammary stem cell self-renewal [15–17].
In addition to the function of cyclin D1 as a regulatory
subunit of a CDK holoenzyme, several CDK independent
functions have been identified. Cyclin D1 also functions as
a transcriptional regulator, usually in a CDK4-independent
manner [8]. Cyclin D1 also mediates DNA-damage repair
signaling in a CDK4-independent manner [18]. Chromatin
immunoprecipitation studies identified cyclin D1 in the
context of local chromatin, and the abundance of cyclin
D1 determined the recruitment of transcription factors (TF)
[19]. The recruitment of cyclin D1 to cis elements enriches
for histone acetylases (p300/CBP), histone deacetylases,
the methylase SUV39 and the heterochromatin protein
HP1α in ChIP [20]. ChIP-ChIP demonstrated cyclin D1
and p300 together occupied genes in close proximity to the
transcriptional start site [21], and whole genome ChIP-Seq
demonstrated enrichment of cyclin D1 at genes that regulate
mitosis and chromosomal stability [22]. In MEFs and in
transgenic mice cyclin D1 induced chromosomal instability
(CIN) gene expression. CIN occurs frequently in tumors [23]
and is characterized by altered rates of loss or gain of whole
chromosomes and/or structural chromosomal aberrations
[24]. However, the contribution of CIN to the molecular
mechanisms governing relatively early changes in tumor
progression remains to be fully understood [25, 26], especially
in an in vivo context. In view of recent findings that cyclin
D1 is capable of inducing aneuploidy and prior findings that
the cyclin D1 kinase function appears to be dispensable for
several activities, and because of the crucial implications of
this mechanism for cancer therapeutics, we determined the
importance of cyclin D1 kinase function in the induction of
CIN and mammary tumorigenesis in vivo.

RESULTS
Cyclin D1 induction of mitotic abnormalities is
kinase-independent
Recent studies using SKY analysis and gene
expression profiling have demonstrated that re-expression
www.impactjournals.com/oncotarget
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Figure 1: Cyclin D1 induction of centrosome amplification and mitotic spindle disorganization is independent of
cyclin D1 kinase activity. (A) Representative confocal maximum Z projections of mitotic cells from cyclin D1-/-Control, cyclin D1-/-D1

and cyclin D1-/-KE Rescue. Cells were immunostained for α-tubulin (red), γ-tubulin (yellow), crest (green), and Hoechst (blue). Scalebar
5 μm. (B) Frequencies of mitotic cells with multiple polar spindles (**p = 0.0051, ***p = 0.0004; calculated by Fisher contingency
test). (C) Frequency of cells with multiple chromosomes (*p = 0.021, ***p = 0.0007; calculated by Fisher contingency test). (D and E)
Spindle measurements on maximum Z projections of metaphase cyclin D1-/-, cyclin D1-/-D1 Rescue and cyclin D1-/-KE Rescue cells. Measurement of
metaphase plate dimensions (DAPI): ChL, chromatin length; ChW, chromatin width (**p = 0.0087, ***p < 0.001). Measurement of spindle
dimensions (tubulin): SpW, spindle width; SpL, spindle length (*p = 0.0486; data are mean of ± SEM).
Rescue

increased in cyclin D1-/-D1 Rescue and cyclin D1-/-KE Rescue cells
compared with cyclin D1-/-Control cells.

of all metaphases (Figures 2A–2C and Supplementary
Figure S3A–S3C). At 72 hours cyclin D1-/-KE Rescue induced
aneuploidy in 42% of cells, compared to 7% in cyclin
D1-/-Control cells. At 120 hours, 100% of cyclin D1-/-KE Rescue
cells demonstrated aneuploidy compared to 70% in cyclin
D1-/-Control MEFs (Figure 2D, and 2F). Therefore, induction
of aneuploidy by cyclin D1 is kinase-independent. SKY
analysis assigns chromosomal rearrangements classified
as deletions, duplications and translocations. There was
no significant difference in chromosomal rearrangements
between cyclin D1-/-Control and cyclin D1-/-KE Rescue MEFs.
To further assess the role of cyclin D1 kinase activity
in aneuploidy induction we transduced MEFs with cyclin

Cyclin D1KE induces aneuploidy
Spectral karyotyping (SKY) was conducted comparing
cyclin D1-/-KE Rescue vs. cyclin D1-/-Control cells. Aneuploidy
refers to the loss or gain of whole or partial chromosomes
resulting in a complement that differs from an exact
multiple of the haploid number. In order to assess the role
of cyclin D1KE in aneuploidy we performed SKY analysis
at 72 hours and 120 hours after rescue of cyclin D1-/- MEFs.
Representative metaphase spreads are shown from analysis
www.impactjournals.com/oncotarget
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D1KE in the presence and absence of a CDK4/6 antagonist,
PD0332991, and assessed the induction of aneuploidy.
Karyotyping was conducted comparing cyclin D1-/-KE Rescue
vs cyclin D1-/-Control cells. Western blot analysis confirmed
CDK4/6 antagonist PD0332991 diminished phosphorylation
of pRB at S780 in cyclin D1-/-Control and cyclin D1-/-KE Rescue
MEFs; cyclin D1-/-D1 Rescue 3T3 cells were used as a positive
control for induction of phosphorylation of pRB at S780
(Supplementary Figure S4A). Representative metaphase
spreads and numerical quantitation are shown from
analysis of all metaphases from PD0332991 and vehicle

treated MEFs (Supplementary Figure S4B). At 72 hours in
presence of vehicle cyclin D1-/-KE Rescue induced aneuploidy in
67% (p = 0.027) of MEF cells, compared to 33% in cyclin
D1-/-Control cells (Supplementary Figure S4C and S4D). At 72
hours in presence of PD0332991, cyclin D1-/-KE Rescue induced
aneuploidy in 87% of cells (p < 0.001), compared to 20% in
cyclin D1-/-Control cells (Supplementary Figure S4C and S4E).
In addition to using a CDK4/6 antagonist we also
investigated the induction of aneuploidy by cyclin D1 in
cdk4/6-/- 3T3 cells. Cdk4/6-/- 3T3 cells were transduced with
cyclin D1WT and cyclin D1KE and we assessed the induction

Figure 2: Cyclin D1 kinase-independent induction of aneuploidy. Representative metaphases from spectral karyotyping (SKY)

on MEFs of cyclin D1-/-Control at 72 hours (P6) (A), cyclin D1-/-KE Rescue at 72 hours (P6) (B) and cyclin D1-/-KE Rescue at 120 hours (C). Each panel
contains the following images: inverted 4’,6-diamidino-2-phenylindole (DAPI) image of the metaphase (top left corner), raw spectral image
of the metaphase (top right) and classified metaphase of the same metaphase (lower panel). (D) Scatter plots of chromosomal number across
metaphase spreads from cyclin D1-/-Control and cyclin D1-/-KE Rescue cells showing the total number of chromosomes at 72 hours and 120 hours
from cells with the noted genotype. The grey shaded bar represents expected deviation from normal at 2N and 4N (+/– 2 chromosomes).
Applying the chi-square test of association by comparing cyclin D1-/- versus the cyclin D1-/-D1 Rescue MEFs, and cyclin D1-/-KE Rescue cells yields
p < 0.001. (E and F) Bar graphs showing the number of normal and abnormal karyotypes comparing cyclin D1-/-Control and cyclin D1-/-KE Rescue
at 72 hours and 120 hours post transduction. (G) An expression profile for cyclin D1-/-D1 Rescue (red line) and cyclin D1-/-KE Rescue (green line)
induced genes [16] enriched for high CIN score (p < 0.0001).
www.impactjournals.com/oncotarget
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of aneuploidy. Western blot analysis of the cell lysates
confirmed the cells were cdk4-/- and expressed exogenous
cyclin D1WT and cyclin D1KE (Supplementary Figure S5A).
At 72 hours in cdk4/6-/- 3T3 cells cyclin D1WT and cyclin
D1KE induced aneuploidy in 67% of cells (p = 0.045) and
83% of cells respectively (p = 0.002), compared to 44% in
cdk4/6-/-Control cells (Supplementary Figure S5B, S5C, and
S5D). Therefore induction of aneuploidy by cyclin D1WT
and cyclin D1KE is CDK independent.
Analysis of microarray data of cyclin D1-/-KE Rescue and
cyclin D1-/-D1 Rescue vs. cyclin D1-/-Control MEFs demonstrated
increased expression of genes associated with a high CIN
score [30]. The CIN score was derived by a computational
approach to define a gene expression signature that
correlates with functional aneuploidy in tumors. The
signature predicted poor outcome in 12 cancer data sets from
six cancer types. The higher CIN score genes regulate the
DNA damage checkpoint, spindle checkpoint and spindle
assembly. The induction of high CIN score genes by cyclin
D1 was independent of its kinase function (Figure 2G).

Therefore, acute expression of cyclin D1KE was sufficient to
induce CIN gene expression profiles within 7 days.

Sustained mammary gland expression of cyclin
D1KE induces tumors independent of kinase
Next we employed mammary gland targeted cyclin D1
for a sustained expression study (Supplementary Figure S6C).
MMTV-cyclin D1KE and MMTV-cyclin D1WT transgenic
mice were monitored twice weekly for the development of
mammary tumors. All mice in the tumor kinetics study were
nulliparous, thus eliminating any potentially confounding
effects of parity on tumor development in the FVB strain.
Mice that developed palpable tumors were sacrificed within
a week of tumor detection. MMTV-cyclin D1KE tumor
incidence (43.8%; n = 32 mice) was similar to MMTVcyclin D1WT (33.3%; n = 48 mice) (p = 0.358) with a 4-fold
(p = 0.0002) and 3-fold (p = 0.0002) greater incidence,
respectively, compared to the wild type mice (n = 92 mice)
(Figure 3D). A Kaplan–Meier survival (Mammary gland
tumor free survival) plot and analyses with a logrank test
for curve comparisons were performed among all three lines
and between paired lines. The event plotted was the date
of sacrifice of the mice that developed tumors. Mice were
censored on the date at which they were no longer followed.
This included, 1) those that died unrelated to tumor prior to
760 days (censored on the date of death) and 2) those alive
without tumor at the end of the study (censored on day 760).
Kaplan–Meier survival plots demonstrated kinetics that was
similar for both MMTV-cyclin D1KE and MMTV-cyclin D1WT
animals (logrank p = 0.237) but significantly different from
wild type mice (p < 0.0001 and p = 0.0037, respectively)
(Figure 3E). Next, we performed histological analysis of the
tumors from MMTV-cyclin D1WT and MMTV-cyclin D1KE
mice. The spectrum of histological subtypes of the mammary
cancers was similar between MMTV-cyclin D1WT and
MMTV-cyclin D1KE mice (Supplementary Table S1). Indeed,
it’s the same spectrum that is seen in the ‘background’ of
mammary cancers developing spontaneously in wild type
mice.
Protein abundance from MMTV-cyclin D1KE
transgene in the mammary tumors was similar to MMTVcyclin D1WT in the mammary gland (Supplementary
Figure S8A). The phosphorylation status of a CDK4/6
target site in pRB was substantially reduced in mammary
gland tumors of MMTV-cyclin D1KE compared to
MMTV-cyclin D1WT tumors (Supplementary Figure
S8B). Gene expression profiles of the mammary tumors
for MMTV-cyclin D1KE and MMTV-cyclin D1WT
mice showed highly significant overlap (p < 1 × 10-10)
(Supplementary Figure S9A–S9C and Dataset S2).
Furthermore, enrichment for CIN gene expression was
observed with both MMTV-cyclin D1WT and MMTVcyclin D1KE (Figure 3F). There were no significant
differences in the CIN score between the MMTV-cyclin
D1WT and MMTV-cyclin D1KE tumors. Conversely,
mammary epithelial cells from transgenic mice with

Acute induction of Cyclin D1KE leads to
expression of high CIN score genes in vivo
To directly determine the role of cyclin D1-mediated
kinase activity in promoting mammary tumorigenesis,
transgenic mouse models were deployed using either the
tetracycline-inducible cyclin D1 transgenic mice (rtTA/
CCND1), the Ponasterone inducible mammary epithelial
cell targeted cyclin D1-antisense or the MMTV-cyclin
D1 transgenic mouse model [12, 22] (Supplementary
Figures S6A and S6C). Mammary-targeted expression
of cyclin D1 was achieved by crossing transgenic
mice carrying a mammary gland targeted recombinant
Tetracycline transcription factor (rtTA-Tet ON system)
to transgenic mice bearing an rtTA-responsive promoter
driving either cyclin D1WT or cyclin D1KE (PTet-CCND1WT
and PTet-CCND1KE). The resulting offspring double
positive for the transgenes were designated rtTA/
CCND1WT and rtTA/CCND1KE (Supplementary Figure
S6B). Pregnant females (14 days post coitus) were treated
with tetracycline for 7 days, followed by sacrifice of the
animals and removal of the thoracic mammary glands for
further studies. Western blot analysis verified the induction
of the cyclin D1 transgene (Figure 3A). Microarray
analysis for gene expression profiles of the mammary
glands identified gene clusters regulated by cyclin D1WT
and cyclin D1KE (Figure 3B, Supplementary Figure S7A
and Dataset S1). There was significant overlap between
the gene expression profile regulated by cyclin D1WT and
cyclin D1KE (p < 1 × 10-10). Pathway analysis of the genes
in common between rtTA/CCND1WT and rtTA/CCND1KE
revealed many functional terms previously identified as
being cyclin D1 regulated including cell cycle and mitosis
(Supplementary Figure S7B). Notably, the rtTA/CCND1WT
gene profile was enriched for high CIN score genes to a
similar level as the rtTA/CCND1KE gene profile (Figure 3C).
www.impactjournals.com/oncotarget
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Figure 3: Cyclin D1 induces CIN genes in vivo and mouse mammary tumorigenesis independent of its kinase activity. (A)

Western blot using anti-FLAG of mammary gland protein lysates from Tet-CCND1WT and Tet-CCND1KE mice treated with doxycycline
compared to control (Left panel). (B) Venn diagram representing genes differentially regulated by Tet-CCND1WT (n = 3) and Tet-CCND1KE
(n = 3) (Right panel). 1-way ANOVA was used to evaluate the significance of differential expression between biological conditions. Data
represents p < 0.05 and fold change in gene expression >1.5. (C) The most highly differentially regulated genes (Fold >2, p < 0.05) for TetCCND1WT (red line) and Tet-CCND1KE (green line) induced genes [16] are enriched for high CIN score (p < 0.0001). (D) Tumor incidence
was markedly increased in MMTV-CCND1WT mice and MMTV-CCND1KE mice compared to WT mice. (E) Kaplan–Meier survival curves
from mammary tumors of MMTV-CCND1WT (red line) and MMTV-CCND1KE (green line). (F) The most highly differentially regulated
genes (Fold >2, B >3) for MMTV-CCND1WT (red line) and MMTV-CCND1KE (green line) induced genes are enriched for high CIN score
(p < 0.0001). mRNA from the mammary glands of ponasterone A inducible cyclin D1 antisense mice [12] were subjected to microarray
analysis demonstrated reduced CIN gene expression for cyclin D1 induced genes (p < 0.0001).

Recruitment of cyclin D1 to local chromatin is
kinase-independent

targeted cyclin D1 anti-sense induced by ponasterone
[12] showed a reciprocal change in CIN gene expression
(Figure 3F), highlighting a role for endogenous
cyclin D1 in maintaining basal CIN gene expression.
Reintroduction of either cyclin D1WT or cyclin D1KE into
cyclin D1-/- MEFs, transient expression in the mammary
gland in transgenic mice, or sustained expression under
control of the MMTV promoter, was sufficient for the
induction of CIN gene expression; therefore these
functions of cyclin D1 are kinase-independent.
www.impactjournals.com/oncotarget

Cyclin D1 regulates transcription factor (TF)
occupancy in chromatin and a cyclin D1-DNA bound
form occupies promoter-regulatory regions in the context
of local chromatin [21, 23]. In order to determine whether
DNA association in chromatin was kinase-dependent we
conducted genome wide analysis comparing the cyclin
D1WT and cyclin D1KE mutant using ChIP-Seq analysis.
6
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Figure 4: Chip-Seq demonstrates similar characteristics of genomic occupancy for cyclin D1KE and cyclin D1WT. (A) Venn

diagram showing distribution of the 4446 intervals with respect to neighboring genes. The interval is depicted in relation to transcriptional
start site (TSS). Upstream of TSS defined as –10 kb to 0 kb. Downstream defined as 0 kb to +10 kb after transcriptional stop site. (B) The
cumulative fraction of intervals from cyclin D1WT and cyclin D1KE mutant that are within the upstream, intergenic or downstream regions of
a gene. (C) Histogram of cyclin D1 bound regions relative to transcriptional start point at –10 kb to +50 kb (Upper panel) and –1 kb to +1
kb (Lower panel). (D) Integrated genome browser visualization of tag density profiles for ChIP-Seq cyclin D1WT and ChIP-Seq cyclin D1KE.
Selected genes are, MLF1 interacting protein (Mlf1ip-a kinetochore platform protein), aurora kinase B (AurkB-member of chromosomal
passenger complex) and zeste white 10 homolog (Zw10-mitotic check point protein).

The distribution of binding sites by ChIP-Seq in relation
to the transcriptional start sites demonstrated binding of
active regions within the promoter-region and beyond 10
kb, consistent with a model in which cyclin D1 localizes
to both very distal elements and promoter proximal
regulatory elements (Figure 4A and 4B) (Supplementary
Table S2 and Dataset S3). The tag density profiles for
cyclin D1WT and cyclin D1KE demonstrated a similar
distribution of genomic association when comparing
location at the promoter, within a gene or downstream of
the transcriptional start site (Figure 4B). In addition, as
in cyclin D1WT, the tag density profiles for cyclin D1KE
were enriched at the transcriptional start sites (Figure
4C). Chip-Seq analysis demonstrated significant overlap
between cyclin D1WT and cyclin D1KE gene occupancy
(1068 genes in common, p = 4.48 × 10-11). Comparison to
a previously published gene set from cyclin D1 associated
www.impactjournals.com/oncotarget

genes by ChIP-ChIP also showed a significant overlap
(1505 intervals in common, p = 0.0018, 1144 genes in
common, p = 1.61 × 10-12 [21]).
Select CIN associated genes showed similar ChIPSeq tag density profiles for cyclin D1WT and cyclin D1KE
(Figure 4D). ChIP analysis of selected target genes
governing CIN demonstrated similar relative occupancy
for cyclin D1WT and cyclin D1KE (Figure 5A). We then
analyzed a broader array of genes governing CIN by QTPCR, demonstrating similar upregulation of the transcript
level by cyclin D1WT and cyclin D1KE (Figure 5B). The
enrichment for transcription factor (TF) binding sites
identified TF motifs and their statistical significance for the
cyclin D1WT and cyclin D1KE (Supplementary Figure 6A
and Supplementary Table S3). For the examples shown the
prevalence of the TF binding site was similar and significant
for both cyclin D1WT and cyclin D1KE. Representative TF
7
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Figure 5: Cyclin D1WT and cyclin D1KE associate with and promotes expression of genes involved in mitosis.

(A) Chromatin immunoprecipitation (ChIP) assay performed to assess the association of cyclin D1WT and cyclin D1KE mutant on the
promoter regions of selected genes. (B) Quantitative PCR on target mRNAs selected based on cyclin D1KE associated genes. Normalized
expression ratio of cyclin D1-/- cells with MSCV-FLAG/CCND1 compared to MSCV-control.

function [34]. In vivo using cyclin D1-/- mice, the
abundance of cyclin D1 was shown to be limiting in
the recruitment of transcription factors in the context
of local chromatin using ChIP assays [19]. ChIP
identified cyclin D1 at transcription factor binding sites
of endogenous gene promoters, associated with the
recruitment of SUV39, HP1α, HDAC 1, 2, and p300
[20, 31]. Cyclin D1 determined the local acetylation
and both di- and tri- methylation of histones [31]. Using
serial ChIP analysis of non-coding miRNA regulatory
regions, cyclin D1 was identified at the regulatory
region of miR17/20 [35]. The current studies are
consistent with a role for a DNA bound form of cyclin
D1 governing gene expression independent of its kinase
function. Furthermore these studies show through
quantitative ChIP-Seq studies similar binding patterns
for cyclin D1 independent of its kinase function to
similar regions of the genome, and similar levels of
binding to individual genes governing CIN.
In the current studies sustained expression of either
cyclin D1WT or cyclin D1KE induced mammary tumors
in transgenic mice with similar kinetics. Consistent with
this experimental evidence for cdk independence of cyclin
D1’s role as a driver oncogene, human breast cancers
overexpressing cyclin D1 do not show high levels of the
canonical E2F target gene cyclin E [4, 5] and exhibit relatively
normal proliferation rates compared to tumors with genetic
deletion of pRb [4–6, 36]. Furthermore, cyclin D1 levels
in tumors do not correlate with the marker of proliferating

motifs most significantly enriched in the cyclin D1WT
intervals are shown for the cyclin D1KE intervals (Figure
6B). In addition to associating with the TF motifs, we
verified that cyclin D1KE regulated the reporter activity of
selected TF responsive elements in a similar manner to
cyclin D1WT (Figure 6C).

DISCUSSION
The current studies demonstrate that transient cyclin
D1 overexpression induces CIN gene expression both in
fibroblasts and in the mammary gland in vivo. Previous
studies had carefully characterized a mutant of cyclin
D1 (cyclin D1KE) demonstrating that it has substantially
decreased cyclin-dependent kinase activity using pRb
as a substrate [28, 29]. In the current studies, the cyclin
D1KE mutant was used to either rescue cyclin D1-/- MEF or
was expressed in the mammary gland of transgenic mice.
Either reintroduction of cyclin D1KE into cyclin D1-/- MEF,
transient expression in the mammary gland in transgenic
mice, or sustained expression under control of the MMTV
promoter, was sufficient for the induction of CIN gene
expression. The induction of CIN gene expression by
cyclin D1KE was indistinguishable from the induction of
CIN gene expression by cyclin D1WT.
D-type cyclins have been shown to physically
bind and to either activate or repress activity of
transcription factors [32–34]. In reporter gene assays
this function was independent of the CDK activating
www.impactjournals.com/oncotarget
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Figure 6: Identification of transcription factor motifs found in cyclin D1WT and cyclin D1KE interval sequences.

(A) Selection of transcription factor motif hits common between Cyclin D1WT and cyclin D1KE interval sequences (B) Representative TF
motifs found in the interval regions associated with cyclin D1WT and cyclin D1KE (C) Luciferase reporter gene assays were conducted using
the Peroxisome Proliferator-Activated Receptor γ (AOX-LUC) (left panel) and Hypoxia Responsive Element (HRE-LUC) (right panel)
luciferase reporter constructs. The number of responsive elements for each construct is depicted in the reporter schematic. HEK293T cells
were co-transfected with cyclin D1 (50 ng). Data are of n = 2 separate experiments, mean ± SEM.

cells, Ki67 [36, 37]. The current studies demonstrate that
forced expression of either cyclin D1WT or cyclin D1KE
give very similar expression patterns of downstream gene
expression, and raise the intriguing possibility that cyclin
D1 primarily contributes to oncogenesis through regulating
a transcriptional program implicated in CIN.
www.impactjournals.com/oncotarget

In contrast, in certain model systems cyclin D1
serves as a mediator of mammary tumorigenesis induced
by other oncogenes such as ErbB2, the role of cyclin
D1 is CDK-dependent. For example, CDK4-/- mice and
cyclin D1KE knock-in mice are resistant to ErbB2-induced
mammary tumorigenesis [14, 29, 38]. Together, these
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studies may illustrate two distinct scenarios reflecting
two distinct clinical-pathological settings. Cyclin D1 is
overexpressed in the majority of human breast tumors,
many of these representing downstream effects through
induction of cyclin D1 by oncogenic signals (Ras, MAPK
[39]), Src [40], ErbB2 [41], STATs [42], Notch [43], NFκB
[44]. Such tumors rely on kinase activity of cyclin D1, and
tumor growth could be abrogated not only by inactivation
of cyclin D1 but also by CDK4/6 inhibition. CDK4/6
inhibitors (Palbociclib, LEE011, LY2835219), currently
in various stages of phase clinical trial, are showing
promise as potential therapies in a range of human
malignancies [45].
In contrast, cyclin D1 is often overexpressed as a
function of genomic rearrangement or amplification. In
this setting cyclin D1 is a primary driver oncogene and
is experimentally recapitulated by targeted cyclin D1
transgene overexpression. Thus, the present evidence for
a CDK-independent role of cyclin D1 in driving mammary
tumorigenesis may be especially relevant to human breast
cancer, particularly the large subset with clonally selected
cyclin D1 gene amplification and potentially the multiple
other types of human tumors similarly driven by cyclin D1
amplification or rearrangement [1]. Accordingly, for these
tumors, direct therapeutic targeting of cyclin D1 would be
predicted to have more efficacy than CDK inhibitors.

confirmation by Southern blotting as described [3]. From
these founders and progeny, two independent lines, called
MFD1 and MFD1-KE, with robust and comparable levels
of transgene expression in mammary tissue as determined
by Northern blotting with a human cyclin D1 cDNA probe
[1, 3], were selected for expansion and long-term analyses
of tumor kinetics. The previously described MMTV-cyclin
D1 (no FLAG tag) line MP1 [3] and FVB wild type (WT)
mice were used as controls as indicated below.
The cDNA of human cyclin D1 including 3xFLAG
sequence was amplified by PCR using p3xFLAG CMV
10-cyclin D1 as template. The restriction sites (Xho I/Not
I) were introduced to the primers. The PCR fragment was
cloned into pF43 vector. To prepare the DNA fragment for
making transgenic mice, the pF43–3xFLAG-cyclin D1
vector was digested with Xho I/Not I/Pvu I. A 2.4-kb DNA
fragment was recovered from agarose gel and purified for
injection. Transgenic founder lines were backcrossed with
wild type FVB mouse for three generations to obtain the
stably inherited transgene line, followed by cross mating
with MMTV-rtTA line (from Dr. Lewis Chodosh’s lab) to
obtain cyclin D1+/+ rtTA+/+ mice (Supplementary Figure
6A and 6B). 6–8 weeks-old female double transgenic mouse
was used for further experiments. 8-week-old tetracyclineinducible cyclin D1/rtTA bi-transgenic pregnant female
mice (12 days postcoitus) were administered doxycycline
in the drinking water to a final concentration of  2 mg/ml.
Following 7 days of doxycycline treatment, the mice were
sacrificed and mammary glands extracted for tissue fixation
and RNA/ protein isolation.

MATERIALS AND METHODS
Cell culture and cell lines
The MSCV-IRES-GFP retroviral vector and cyclin
D1 wild-type constructs were previously described [46].
Cyclin D1+/+ and cyclin D1−/− primary MEF cultures were
prepared as described previously. Cells were maintained in
DMEM supplemented with 10% fetal bovine serum, 100
μg/ml each of penicillin and streptomycin. Cdk4/6-/- 3T3
cells were a gift from Dr. M. Barbacid.

Retrovirus production and infection

Generation of transgenic mice

Detailed methods of chromatin preparation, labeling
and construction of libraries have been documented
previously [22]. For ChIP-Seq analysis, the 35-nt sequence
reads (“tags”) identified by Illumina’s Genome Analyzer 2
are mapped to the genome using the ELAND algorithm.
Only tags that map uniquely, have no more than 2
mismatches, and that pass quality control filtering are used
in the subsequent analysis. Since the 5’-ends of the sequence
tags represent the end of ChIP/IP-fragments, the tags are
extended in silico (Genpathway software) at their 3’-ends to
a length of 110 bp, which is the average fragment length in
the size selected library. To identify the density of fragments
(extended tags) along the genome, the genome is divided
into 32-nt bins and the number of fragments in each bin is
determined. The ChIP-Seq peak intervals were determined
using the MACs version 1.4 algorithm. We used the default
values and provided the FLAG experiment with IgG as a

Retroviral production and infection of cyclin
D1−/− MEFs cells were described in detail previously [46].

ChIP-Seq analysis and transcription factor
enrichment

Two 8 amino acid FLAG tagged constructs were
prepared using either human cyclin D1 cDNA (pPL-8)
[2] or an otherwise identical cyclin D1 cDNA bearing the
“KE” mutation - an AAG to GAG that changes K (lysine)
to E (glutamic acid) at amino acid 112, blocking cyclin D1
associated kinase activity. These constructs were inserted
into the previously described MMTV-Sv40-BSSk vector [3]
(see Supplementary Figure 1A and 5C) and its SalI—SpeI
linearized fragment which included MMTV-LTR, the FLAG
tagged construct, plus SV40 intron and polyadenylation
signals, was microinjected into fertilized FVB/N mouse
oocytes and implanted into pseudopregnant FVB fosters
using standard methods. Pups were examined for successful
insertion of the respective transgenes using tail genomic
DNA and PCR primers for the SV40 cassette with
www.impactjournals.com/oncotarget
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background dataset. We used a p-value of 1.0E-5 as the
cutoff for peak detection, which identified 4296 intervals.
Supplementary Dataset 1 provides a further summary of
the number of intervals found and their position relative to
mouse genes. We used the DAVID Functional Annotation
Tool to annotate functional enrichment. Transcription factor
binding sites were computed as previously described [22].
In order to find the transcription factor binding sites
we downloaded the latest version of the mouse genome,
mm9, which was released in July 2007 from the USCS Main
Genome Browser [47]. Using the Galaxy Toolbox [48] we
extracted the sequence 10 kb upstream and downstream of
each gene and submitted them to the Jasper server [49] with
the default parameters to find all vertabrate transcription
factor binding sites. We then assessed the overlap between
these transcription factor binding sites and the cyclin
D1KE peak intervals. We used a permutation test initially
proposed by Tuteja et al, [50]. In brief, this test involves
creating psuedo-random in silico ChIP-Seq experiments
that accurately reflects a null model of random binding. We
shuffled the locations of the windows obtained from the cyclin
D1KE ChIP-Seq experiment and then counted the observed
number of transcription factor binding sites. We calculate the
p-value as the fraction of times in which the random count
is larger then the observed count. For this experiment we
performed 1.0E + 9 random permutations.
To determining overlap between cyclin D1WT and
cyclin D1KE cyclin D1 binding-sites we used both a genebased method and an interval based method. For the interval
based method we used the same permutation method as
described for the transcription factor enrichment to determine
the overlap between the cyclin D1WT and the cyclin D1KE
mutant binding sites. We used the intervals published
previously for the cyclin D1WT intervals [22]. Significance
of overlap between cyclin D1KE set and ChIP-ChIP data
set [21] calculated using the same approach. For the genebased method we used a hypergeometric test to determine
the probability that cyclin D1WT and cyclin D1KE intervals are
located in the promoter region or 2 kb upstream of the same
genes.
In order to further examine the similarity of the
enriched transcription factors we examined the number
of transcription factor binding sites within the promoter
region of each gene and in the cyclin D1WT or cyclin D1KE
intervals. We then fit the difference in the counts between
the corresponding transcription factors to a distribution
using a Gaussian kernel density estimator [51]. Due to
the discrete nature of the distribution we truncated to
the maximum difference, 855 counts in this case, and
re-normalized the distribution. We then calculated the pvalue for each transcription factor as 1-cdf (delta).

Briefly, 3 × 10 cm plates of actively growing late passage
MEFs cyclin D1-/- MSCV-IRES-cyclin D1 were fixed for
10 min with paraformaldehyde 37% (final concentration
1%). Unreacted formaldehyde was quenched with 1 ml
of 10 × glycine. The 3 plates were washed twice with ice
cold PBS and the pellets harvested in 1 ml of PBS with
protease inhibitor cocktail and pooled together in a 15 ml
tube in order to obtain 1.5 × 106 cells. DNA fragmentation
of the pellets was achieved by sonication, 35 cycles of
20 seconds each at maximum speed using OMNI-Ruptor
4000 (OMNI International, Inc, Kennesaw, GA). Immunoprecipitation (IP) was performed with 10 μg of M2 FLAG
antibody (Sigma-Aldrich, St. Louis, MO) and equivalent
amount of mouse IgG as negative control. Washes and
elution of the IP-DNA were performed according to the
protocol. PCR primers were designed based on the peak
interval sequence associated with cyclin D1 and the PCR
products were visualized by agarose gel electrophoresis.
ChIP-DNA quantitation was conducted in an Agilent
2100 bio analyzer (Agilent Technologies, Palo Alto, CA),
using Power SYBR Green (AB biosciences, Allston,
MA) according to the manufacturer’s guidelines. Equal
quantities of ChIP-DNA were used for the real-time PCR
quantitation. Ct values were used to calculate the relative
fold enrichment (2-ΔCt, ΔCt = Ctinput–CtIgG). A one
way ANOVA followed by Student’s t-test comparison was
performed to compare the relative fold enrichment (n = 3).

Karyotype analysis
For SKY analysis, fluorescence color images of
chromosomes stained by Rhodamine, Texas Red, Cy5,
FITC and Cy5.5 were captured under a Nikon microscope
equipped with a spectral cube and Interferometer module.
SKY View software (version 1.62), was used to analyze
chromosomal number and structural alterations of
chromosomes, including simple balanced translocations,
unbalanced (or nonreciprocal) translocations, deletions
and duplications. At least 10 metaphases were analyzed
per sample. Statistical significance calculated using chisquare test of association (Pearson).

Real-time PCR
RNA quantitation was conducted in an Agilent
2100 bio analyzer (Agilent Technologies, Palo Alto, CA),
using Power SYBR Green (AB biosciences, Allston, MA)
according to the manufacturer’s guidelines. Equal quantities
of RNA were used for the reverse transcription reactions.
Primers for all the genes were designed using GenScript’s
bioinformatics tools (GenScript, Piscataway, NJ).

Microarray analysis

Chromatin immuno-precipitation assay (ChIP)

Genes with differential expression p-value ≤ 0.01
and absolute fold change ≥ 1.25). Mouse MG_U74Av2
microarrays were used for MSCV-rescued MEFs, Mouse

ChIP material was prepared in accordance with
the Magna ChIP (Millipore) manufacturer’s guidelines.
www.impactjournals.com/oncotarget
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430A_2 microarrays were used for MMTV-Cyclin D1
model (GEO accession number—GSE43216). Arrays
were processed as previously described [22]. CIN score
enrichment was conducted as described, the comparison
to CIN curves from Tet-CCND1WT and MMTV-CCND1WT
has been published previously.
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Western blotting and luciferase assays
The following antibodies were used for Western
blotting: Guanine Nucleotide Dissociation Inhibitor
(GDI) [40], Cyclin D1 (NeoMarkers, MS-210-P), FLAG
M2 antibody (Sigma Aldrich, #F1804), β-Tubulin (Sigma
Aldrich, T4026), phosphorylated RB (S780) (Cell
Signaling), cdk4 (H-22) (Santa Cruz Biotechnology Inc.).
Luciferase assays were conducted as described previously
described [52]. Assays were conducted using 50 ng of
plasmid DNA and 100 ng reporter plasmid.
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